“eXoZymes represents a new generation of synthetic biology design and scale-up,” Perriman said. He highlighted the company’s potential to set new standards for development speed and product opportunities. Perriman noted that their innovative approach overcomes the limitations of conventional technologies, enabling projects to reach commercial scale more quickly and with lower capital risk.
